Amgen Announces Webcast of 2005 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2005 Fourth Quarter and Full Year Financial Results
Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased 29 Percent to 75 Cents; Full Year 2005 Adjusted Earnings Per Share Increased 33 Percent to $3.20 Read more about Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased 29 Percent to 75 Cents; Full Year 2005 Adjusted Earnings Per Share Increased 33 Percent to $3.20
Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial Results
Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 Percent to 72 Cents Read more about Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 Percent to 72 Cents
Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease Read more about Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty Read more about Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
New Phase 3 Data Show Potential Benefits of Aranesp(R) Dosed Every Three Weeks for Chemotherapy-Induced Anemia; Aranesp Treatment Achieved and Maintained Target Hemoglobin Levels and Reduced Incidence of Red Blood Cell Transfusions Read more about New Phase 3 Data Show Potential Benefits of Aranesp(R) Dosed Every Three Weeks for Chemotherapy-Induced Anemia; Aranesp Treatment Achieved and Maintained Target Hemoglobin Levels and Reduced Incidence of Red Blood Cell Transfusions
Interim Long-Term Follow-up Data Show AMG 531 Increases Platelets in Patients with Immune Thrombocytopenic Purpura; Results Suggest Once-Weekly Dosing of AMG 531 Results in Sustained Platelet Response Read more about Interim Long-Term Follow-up Data Show AMG 531 Increases Platelets in Patients with Immune Thrombocytopenic Purpura; Results Suggest Once-Weekly Dosing of AMG 531 Results in Sustained Platelet Response
Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients with Myelodysplastic Syndrome (MDS); Patients with Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue Read more about Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients with Myelodysplastic Syndrome (MDS); Patients with Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
The Wellness Community and Amgen Partner with Professional Cyclist George Hincapie to Launch 'Breakaway from Cancer' Initiative Read more about The Wellness Community and Amgen Partner with Professional Cyclist George Hincapie to Launch 'Breakaway from Cancer' Initiative
